scholarly journals Sequential Treatment Reduces the Acute Phases of Adverse Effect of Zoledronic Acid in First Time Users

2018 ◽  
Vol 08 (07) ◽  
pp. 189-205
Author(s):  
Jinmei Deng ◽  
Dongmei Cai ◽  
Suming Jie ◽  
Enjing Chen ◽  
Xiuzhen Cai ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Zoledronic Acid ◽  
Sequential Treatment ◽  
First Time

Managing the Transition to Edentulousness Using Partial Transitional Dentures for First Time Prosthodontic Patients: Addressing Unrealistic Expectations – A Case Report

2017 ◽  
Vol 1 (1) ◽  
Keyword(s):  
Case Report ◽  
Treatment Outcomes ◽  
Treatment Planning ◽  
Clinical Relevance ◽  
Treatment Plan ◽  
Sequential Treatment ◽  
Aesthetic Result ◽  
Abutment Teeth ◽  
First Time ◽  
Unrealistic Expectations

Aim: The aim of this report is to describe the management of a prosthodontic patient expressing unrealistic expectations with respect to the transition to edentulousness. Objectives: To outline (1) the diagnosis and explicit expectations of the patient on presentation (2) considerations made during treatment planning to address the wishes of the first time prosthodontic patient (3) a sequential treatment plan utilizing transitional partial removable dentures to manage the change to edentulousness (4) functional and aesthetic result achieved. Results: Delivery of immediate removable partial dentures retaining key abutment teeth in upper and lower arches was a viable prosthodontic solution in the transition to edentulousness of a patient expecting unrealistic treatment outcomes. Conclusions: Addressing impractical expectations and devising a treatment plan amenable to both clinician and patient is difficult. Strategies to manage these wishes in prosthodontic dentistry can include transitional partial dentures. Clinical relevance: Practitioners who encounter similar situations may consider this report valuable.

scholarly journals Adipose-Derived Stem Cells in Crohn's Rectovaginal Fistula

2010 ◽  
Vol 2010 ◽  
pp. 1-3 ◽  
Author(s):  
D. García-Olmo ◽  
D. Herreros ◽  
P. De-La-Quintana ◽  
H. Guadalajara ◽  
J. Trébol ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Adipose Derived Stem Cells ◽  
Vaginal Fistula ◽  
History Of ◽  
First Time

Therapeutic options for recto-vaginal fistula in the setting of Crohn's disease are limited and many data are available in the literature. The manuscript describes the history of a patient who has been the pioneer of our Clinical Trials in treating this disease in fistulizing Crohn's disease environment. We believe it is the first time that a patient with this disease has been treated by adipose-derived stem cells in allogeneic form. The conclusion of our study with Mary is that the use of mesenchymal stem cells derived from adipose tissue is secure, either in autologous or allogeneic form. Furthermore, we have proved that if we use multi-dose and multiple applications on a patient, it does not produce any adverse effect, which confirms us the safety of using these cells in patients at least in the fistulizing Crohn's disease environment.

In vivo perspective study about the effects of weekly low dose administration of zoledronic acid (ZA) on angiogenesis

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 3558-3558
Author(s):  
D. Santini ◽  
B. Vincenzi ◽  
F. Battistoni ◽  
S. Galluzzo ◽  
L. Rocci ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Cancer Patients ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Low Doses ◽  
Dose Administration ◽  
Before And After ◽  
Endothelial Growth Factor ◽  
First Time

3558 Purpose: Recent data have demonstrated in preclinical tumor models an antiangiogenic and antitumor activity of low weekly doses of ZA. As a consequence, the purpose of this study was to confirm these data, evaluating in cancer patients the modifications in angiogenic cytokines levels following repeated weekly low doses of ZA. Experimental Design: 26 consecutive cancer patients with bone metastases treated, for the first time, with four weekly doses of 1 mg of ZA followed by standard doses (4 mg every 28 days) were prospectively evaluated for circulating levels of vascular endothelial growth factor (VEGF) at different time points: just before and after 1, 7, 14, 21, 28, 56 and 84 days following the first disphosphonate infusion. Results: Basal serum VEGF median levels were significantly decreased just after 7 days (-29.7%) (with only one weekly infusion) (P=0.038), This significant decrease of circulating VEGF levels persisted 14(-33.2%), 21 (-39.4%), 28(-31.8%), 56(-33.6%) and 84(-27.9%) days after the first infusion (respectively, P=0.002, P=0.001, P=0.008, P=0.002, P=0.014). Conclusions: This study confirms, for the first time in humans, that weekly low doses of zoledronic acid could have antiangiogenic properties through a significant and long lasting decrease of VEGF serum levels. No significant financial relationships to disclose.

Osteonecrosis of the jaw (ONJ) in radium 223 (Ra223)-treated metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with exposure to zoledronic acid and/or denosumab.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 5575-5575
Author(s):  
Yen Thi Kim Hong Cao ◽  
Janson Trieu ◽  
Vanessa Rojas ◽  
Michael Elias ◽  
Michael J. Anderson ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Metastases ◽  
Data Entry ◽  
Sequential Therapy ◽  
Median Number ◽  
Osteonecrosis Of The Jaw ◽  
Sequential Treatment ◽  
Castration Resistant Prostate Cancer ◽  
Radium 223 ◽  
Sequential Group

5575 Background: Bone health agents (BHA) including denosumab, a monoclonal antibody, and Zoledronic acid (ZA), a bisphosphonate, are recommended for men with CRPC and bone metastases to prevent skeletal-related complications. ONJ occurs in about 5% of patients (pts) on BHA. The incidence of ONJ in pts treated with Ra223 and BHA remains unknown, particularly in those who receive sequential treatment of BHAs. Here we describe the rate of ONJ in a real-world setting in mCRPC pts treated with Ra223 in 3 groups: 1) denosumab alone, 2) ZA alone, and 3) sequential ZA /denosumab or vice versa. Methods: A retrospective analysis of a cohort of mCRPC pts with bone metastases who received Ra223. Follow-up was until date of death or last data entry. Chart inclusion criteria included patients who received Ra223 between November 2010 to August 2018 with documentations of data points. Results: A total of 177 pts received Ra223 between 11/2010 and 8/2018. Median age 73 at 1st Ra223 (range 40-93); Median PSA 15.8- at 1st Ra223 (range 0.1-1952); Demographics-AA-10, C-130, Asian-9, unspecified-28; Median Alk Phos 95 at 1st Ra233 (range 25-1515). 93 % (164/177) received BHA. Of the 164 who received BHA, 45% (73/164) received denosumab only, 37% (61/164) received ZA only, and 18% (30/164) received sequential treatment. ONJ developed in 9.7% (16/164) of all patients on BHA. Denosumab alone caused ONJ in 7 of 73 pts (9.6%). ZA alone caused ONJ in 6 of 61 pts (9.8%). ONJ occurred in 3 of 30 pts (10%) in the sequential group. The median number of doses of BHA before development of ONJ was 10 with denosumab, 20 with ZA, and 19.5 (denosumab) and 22 (ZA) in the sequential group. Conclusions: In patients treated with Ra223 and a BHA, the rate of ONJ is 9.7%. The rate of ONJ was similar in groups treated with denosumab alone, ZA alone, and sequential treatment of ZA and denosumab However, ONJ developed more quickly in patients on denosumab. We conclude that the risk of ONJ is increased in patients treated with Ra223 and BHA. ZA or sequential therapy appears to delay time to onset of ONJ compared to denosumab. Clinicians should be mindful of the toxic synergy between Ra223 and BHA. ZA may be the preferred BHA partner with Ra223.

A New Look at the Jurisdiction in ALCOA

1967 ◽  
Vol 61 (2) ◽  
pp. 558-570 ◽  
Author(s):  
John M. Raymond
Keyword(s):  
United States ◽  
Adverse Effect ◽  
The United States ◽  
Sherman Act ◽  
Aluminum Company ◽  
Antitrust Laws ◽  
Foreign Corporations ◽  
American Party ◽  
First Time ◽  
Foreign Corporation

One of the best-known antitrust decisions in the last quarter of a century is United States v. Aluminum Company of America et al., now usually referred to as the ALCOA case. Although the Sherman Act had for some time been given an extraterritorial application when American corporations were involved, the novelty of ALCOA was that the decision, written by that eminent jurist, Judge Learned Hand, for the first time interpreted our antitrust laws as rendering illegal contracts of a foreign corporation which were made abroad with other foreign corporations and which related to business carried on and to acts to be performed abroad. No American party was involved, and no act took place in the United States, in the part of the case that is here to be considered. Jurisdiction was claimed merely on the basis of an adverse “effect” on our foreign and domestic commerce.

Glycerol decreases the integrity of the perinuclear theca in boar sperm

Zygote ◽  
2012 ◽  
Vol 21 (2) ◽  
pp. 172-177 ◽  
Author(s):  
Marco Antonio Arenas Núñez ◽  
María de Lourdes Juárez-Mosqueda ◽  
Oscar Gutiérrez-Pérez ◽  
Santiago René Anzaldúa Arce ◽  
Alejandro Córdova Izquierdo ◽  
...  
Keyword(s):  
Electron Microscopy ◽  
Adverse Effect ◽  
Protease Inhibitors ◽  
Free Group ◽  
Glycerol Concentration ◽  
Boar Sperm ◽  
Perinuclear Theca ◽  
First Time ◽  
Control Samples

SummaryWe evaluated the effect of glycerol on the perinuclear theca (PT) of boar sperm. Samples from six ejaculates obtained from three different boars were incubated in the detergent Brij 36-T. Spermatozoa were treated with a glycerol concentration of either 2 or 4%, and incubated for 10 or 30 min; two other samples were treated with protease inhibitors (PI; leupeptin or an inhibitor commercial cocktail), mixed with 4% glycerol, and incubated for 30 min. A third glycerol-free group was used as the control. The samples were processed for electron microscopy evaluation. The PT remained intact in 78% of the control samples while, after addition of glycerol for 30 min, the proportion of spermatozoa with disrupted or absent PT increased (P < 0.05). PT was preserved in PI samples, but PT changes increased (P < 0.05). Differences due to treatment with glycerol (2 or 4%) at 10 or 30 min were not observed. These results show, to our knowledge for the first time, the adverse effect of glycerol on the integrity of the PT.

A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report

2020 ◽  
Vol 15 (1) ◽  
pp. 69-72
Author(s):  
Stefano Dastoli ◽  
Luigi Francesco Iannone ◽  
Luigi Bennardo ◽  
Martina Silvestri ◽  
Caterina Palleria ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Erectile Dysfunction ◽  
Sexual Dysfunction ◽  
Rare Case ◽  
Interleukin 17 ◽  
Inflammatory Condition ◽  
Biologic Drugs ◽  
Drug Induced ◽  
First Case ◽  
First Time

Background: Psoriasis is a cutaneous inflammatory condition characterized by an altered turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic drugs inhibiting interleukin-17. Objective: We report the first case, according to Naranjo score, of a secukinumab-induced erectile dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug (ixekizumab). Methods: A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17. The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days. Results: Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete skin clearance. Conclusion: We describe for the first time a sexual dysfunction possibly due to secukinumab and its resolution after the switch to another similar but different drug, highlighting the potential difference between anti-IL17A drugs.

Sequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats

Climacteric ◽  
2013 ◽  
Vol 17 (4) ◽  
pp. 478-485
Author(s):  
M. L. Brance ◽  
L. R. Brun ◽  
V. E. Di Loreto ◽  
M. Lupo ◽  
A. Rigalli
Keyword(s):  
Zoledronic Acid ◽  
Sequential Treatment

scholarly journals Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study

SLEEP ◽  
2019 ◽  
Vol 42 (11) ◽  
Author(s):  
Yves Dauvilliers ◽  
Isabelle Arnulf ◽  
Zoltan Szakacs ◽  
Smaranda Leu-Semenescu ◽  
Isabelle Lecomte ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Weight Gain ◽  
Sleep Paralysis ◽  
Open Label ◽  
Safety And Efficacy ◽  
Titration Period ◽  
Secondary Endpoints ◽  
First Time ◽  
Histamine H3

Abstract Study Objectives To asses the long-term safety and efficacy of pitolisant, an histamine H3-receptor antagonist, on narcolepsy. Methods This open-label, single-arm, pragmatic study, recruited adult patients with narcolepsy and Epworth Sleepiness Scale (ESS) score ≥12. After a titration period, patients were treated for up to 1 year with oral pitolisant once-a-day at up to 40 mg. Concomitant stimulants and anti-cataplectic agents were allowed. The primary endpoint was safety; secondary endpoints included ESS, cataplexy, and other diary parameters. Results Patients (n = 102, 75 with cataplexy) received pitolisant, for the first time in 73 of them. Sixty-eight patients (51 with cataplexy) completed the 12-month treatment. Common treatment-emergent adverse events were headache (11.8% of patients), insomnia (8.8%), weight gain (7.8%), anxiety (6.9%), depressive symptoms (4.9%), and nausea (4.9%). Seven patients had a serious adverse effect, unrelated to pitolisant except for a possibly related miscarriage. One-third of patients stopped pitolisant, mostly (19.6%) for insufficient benefit. ESS score decreased by 4.6 ± 0.6. Two-thirds of patients completing the treatment were responders (ESS ≤ 10 or ESS decrease ≥ 3), and one third had normalized ESS (≤10). Complete and partial cataplexy, hallucinations, sleep paralysis, and sleep attacks were reduced by 76%, 65%, 54%, 63%, and 27%, respectively. Pitolisant as monotherapy (43% of patients) was better tolerated and more efficacious on ESS than on add-on, but efficacy was maintained in this last case. Conclusions Long-term safety and efficacy of pitolisant on daytime sleepiness, cataplexy, hallucinations, and sleep paralysis is confirmed.

Sign in / Sign up

Export Citation Format

Share Document